BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23092325)

  • 1. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.
    Tibullo D; Barbagallo I; Giallongo C; La Cava P; Parrinello N; Vanella L; Stagno F; Palumbo GA; Li Volti G; Di Raimondo F
    Curr Pharm Des; 2013; 19(15):2765-70. PubMed ID: 23092325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
    Mayerhofer M; Gleixner KV; Mayerhofer J; Hoermann G; Jaeger E; Aichberger KJ; Ott RG; Greish K; Nakamura H; Derdak S; Samorapoompichit P; Pickl WF; Sexl V; Esterbauer H; Schwarzinger I; Sillaber C; Maeda H; Valent P
    Blood; 2008 Feb; 111(4):2200-10. PubMed ID: 18024796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
    Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J
    J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia.
    Mayerhofer M; Florian S; Krauth MT; Aichberger KJ; Bilban M; Marculescu R; Printz D; Fritsch G; Wagner O; Selzer E; Sperr WR; Valent P; Sillaber C
    Cancer Res; 2004 May; 64(9):3148-54. PubMed ID: 15126353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heme oxygenase-1 reduces the sensitivity to imatinib through nonselective activation of histone deacetylases in chronic myeloid leukemia.
    Wei D; Lu T; Ma D; Yu K; Li X; Chen B; Xiong J; Zhang T; Wang J
    J Cell Physiol; 2019 Apr; 234(4):5252-5263. PubMed ID: 30256411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
    Sorrenti V; Pittalà V; Romeo G; Amata E; Dichiara M; Marrazzo A; Turnaturi R; Prezzavento O; Barbagallo I; Vanella L; Rescifina A; Floresta G; Tibullo D; Di Raimondo F; Intagliata S; Salerno L
    Eur J Med Chem; 2018 Oct; 158():937-950. PubMed ID: 30261468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia.
    Salerno L; Romeo G; Modica MN; Amata E; Sorrenti V; Barbagallo I; Pittalà V
    Eur J Med Chem; 2017 Dec; 142():163-178. PubMed ID: 28756878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
    Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
    Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
    J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of HO-1 gene expression on proliferation of imatinib resistant CML cells].
    Wang JS; Chai BS; Fang Q; He YY; Chen C; Yang C
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):388-91. PubMed ID: 21781496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
    Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
    Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
    Baran Y; Ural AU; Gunduz U
    Hematology; 2007 Dec; 12(6):497-503. PubMed ID: 17852433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway.
    Cao L; Wang J; Ma D; Wang P; Zhang Y; Fang Q
    Biomed Pharmacother; 2016 Mar; 78():30-38. PubMed ID: 26898422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
    Tolomeo M; Grimaudo S; Di Cristina A; Pipitone RM; Dusonchet L; Meli M; Crosta L; Gebbia N; Invidiata FP; Titone L; Simoni D
    Cancer Lett; 2008 Jul; 265(2):289-97. PubMed ID: 18374481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.